Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Short Interest Up 46.6% in February

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 66,700 shares, a growth of 46.6% from the February 13th total of 45,500 shares. Based on an average trading volume of 6,080,000 shares, the short-interest ratio is presently 0.0 days. Currently, 1.6% of the shares of the company are short sold.

Phio Pharmaceuticals Stock Up 5.8 %

Shares of NASDAQ:PHIO traded up $0.08 during trading on Monday, reaching $1.37. 63,483 shares of the company traded hands, compared to its average volume of 7,536,588. The firm has a market capitalization of $9.40 million, a PE ratio of -0.13 and a beta of 1.28. The company’s 50 day moving average is $1.98 and its two-hundred day moving average is $2.51. Phio Pharmaceuticals has a 52 week low of $1.22 and a 52 week high of $9.99.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Phio Pharmaceuticals in a research note on Wednesday, February 19th.

Institutional Investors Weigh In On Phio Pharmaceuticals

An institutional investor recently bought a new position in Phio Pharmaceuticals stock. Virtu Financial LLC purchased a new position in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned approximately 0.59% of Phio Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 57.31% of the company’s stock.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.